AbbVie Closes $10.9 Billion Apogee Deal; Earnings Payoff Starts in 2032

NEW YORK, September 5, 2026, 10:10 a.m. EDT

AbbVie NYSE:ABBV has closed its $10.9 billion purchase of Apogee Therapeutics NASDAQ:APGE. The payoff, by AbbVie’s own forecast, will take six years.

The transaction is expected to cut adjusted earnings by $0.46 a share next year. AbbVie does not expect earnings accretion until 2032, according to its September 3 completion notice.

That delay makes the deal a test of patience, not this quarter’s profit. Investors are buying a long-dated immunology option while Skyrizi and Rinvoq fund the wait.

AbbVie shares closed Friday at $256.46, down 1.4% for the day. They remain 18.5% above their June 18 close, the last session before the deal became public.

The market is closed for the weekend. U.S. shares next trade Tuesday after the Labor Day holiday, under the NYSE calendar.

Chief Executive Robert Michael called completion “an important step in further strengthening AbbVie’s leadership in immunology and advancing our long-term growth strategy.” The company statement also kept 2026 adjusted EPS guidance at $13.87 to $14.07.

A growing franchise is financing the gamble

AbbVie enters this bet with unusual operating momentum. Second-quarter immunology revenue rose 15.1% to $8.79 billion, its latest results showed.

Skyrizi generated $5.51 billion, up 24.4%. Rinvoq added $2.53 billion and grew 24.5%.

Humira, once AbbVie’s core engine, fell 35.9% to $756 million. The replacement cycle is working faster than the old franchise is shrinking.

That growth matters because Apogee brought no approved product. Its lead drug, zumilokibart, is entering late-stage testing for atopic dermatitis.

The purchase price was $135.11 a share in cash. AbbVie valued the transaction at $10.1 billion after acquired cash and marketable securities.

Debt will fund the purchase. At June 30, AbbVie had $6.57 billion of cash and $70.82 billion of current and long-term debt, its quarterly filing showed.

The company subsequently arranged a $10 billion, 364-day unsecured term loan. It targets net leverage of two times within two to three years.

The clinical signal is real, but early

Zumilokibart’s Phase 2 study enrolled 346 adults with moderate-to-severe atopic dermatitis. At week 16, 65.9% on the selected mid-dose achieved EASI-75.

The placebo result was 23.4%. The trial met its primary and secondary endpoints, Apogee’s May data release said.

There is a catch. AbbVie’s cross-trial comparisons against marketed biologics were not head-to-head tests.

Three planned Phase 3 dermatitis studies each target about 400 patients. Success could support maintenance injections every three or six months.

Jonathan Silverberg, a George Washington University dermatology professor, cited the “potential for sustained disease control with less frequent dosing.” He was an investigator quoted in the same Apogee release.

That convenience is central to the valuation. It will matter only if larger trials confirm efficacy and safety.

William Blair analyst Matt Phipps offered another explanation for the timing. The acquisition lets AbbVie “accelerate Phase 3 development” and reduce potential Blackstone royalties, he wrote in a note cited by William Blair on June 23.

Still, the valuation leaves little room for clinical delay. Apogee lost $85.9 million in the June quarter and spent $67.3 million on research, according to its last standalone report.

The next debate is therefore measurable. Investors must watch Phase 3 enrollment, the debt bridge and Skyrizi-Rinvoq growth together.

Clinical failure would erase much of Apogee’s value. Slower launches or heavier interest costs could also push the 2032 payoff further out.

For now, AbbVie’s stock says shareholders will wait. The operating business must keep earning that patience.